Cremalax

Quick links to important sections

Cremalax

Method of action: Laxative

Treatment option: Constipation, Proctitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cremalax

Cremalax is a pharmaceutical preparation defined by its core active component, Sodium Picosulfate, which is classified as a stimulant laxative. Its primary function is to provide targeted, short-term relief from occasional constipation and to facilitate thorough bowel cleansing prior to medical procedures.


Quick Facts

Property Description
Active ingredient Sodium Picosulfate
Form Tablet, Oral solution/syrup
Pharmacological class Stimulant Laxative, Contact Laxative
Common use Short-term relief of constipation
Origin Synthetic, Prodrug

What Type of Medicine is Cremalax and What Class Does it Belong To?

Cremalax is a synthetic medicinal agent that belongs to the stimulant laxative pharmacological class, specifically acting as a contact laxative. Sodium Picosulfate works by stimulating the movement of the large intestine, an action that enhances the propulsive activity or motility of the colonic mucosa. Unlike bulk-forming laxatives, this method does not rely on increasing the fecal mass volume. The preparation is frequently marketed as an over-the-counter (OTC) option in certain regions, distinguishing its accessibility from prescription-only agents, and is commonly used by the general patient population to quickly address temporary bowel irregularities.


Is Sodium Picosulfate a Single-Ingredient Prodrug?

The active ingredient, Sodium Picosulfate (INN), is administered orally as a single-ingredient product (monotherapy), and is available in forms such as a tablet and an oral solution (liquid/syrup). It is considered a prodrug because it is chemically inactive upon ingestion. Sodium Picosulfate requires conversion by colon bacteria to its active form (4,4'-dihydroxydiphenyl-(2-pyridyl)methane or DPM) to produce its therapeutic effect. This delayed, targeted activation ensures the stimulating effect is concentrated precisely in the large intestine to promote motility and assist in the softening of feces by limiting the reabsorption of water.

What side effects are possible with Cremalax?

Side Effects and Safety Profile of Cremalax

Cremalax, which contains sodium picosulfate, has an established safety profile primarily involving gastrointestinal effects. Users may experience common adverse reactions, including abdominal pain, cramps, discomfort, and diarrhea.

Less common side effects documented in regulatory summaries are nausea and vomiting.

Adverse Reaction Frequency Examples of Documented Effects
Common Abdominal pain, cramping, diarrhea
Uncommon Nausea, vomiting
Rare Hypersensitivity reactions (e.g., skin rash, angioedema)

Serious and Clinically Significant Adverse Reactions

Overuse or excessive dosing, especially for prolonged periods, can lead to serious risks, including severe dehydration and electrolyte imbalance (such as hypokalaemia, or low potassium levels). These imbalances can affect cardiac function and may rarely lead to complications such as seizures or cardiac arrhythmia.

Rarely, severe hypersensitivity reactions (allergic reactions) that involve swelling of the face, mouth, or throat, and difficulty breathing have been reported and require immediate medical attention.

Safety Restrictions and Special Populations

Cremalax is contraindicated (should not be used) in patients with pre-existing conditions such as severe dehydration, intestinal obstruction (ileus), gastrointestinal ulceration or perforation, or acute inflammatory abdominal diseases (like appendicitis). It is generally not recommended for children under 10 years of age.

Caution is advised in patients with kidney disease, heart disease, and in the elderly due to their increased susceptibility to the risks of dehydration and fluid/electrolyte disturbance. Prolonged use (typically exceeding one week) is discouraged due to the risk of dependence for bowel function and exacerbating electrolyte loss.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosing on this product, which contains sodium picosulfate, involves taking significantly more than the prescribed dose or engaging in prolonged overuse. The primary and most serious risks associated with an overdose stem from its effect on the gastrointestinal tract and fluid balance.

Documented Overdose Presentations

Symptoms of an overdose are primarily related to severe gut stimulation and the subsequent loss of fluids and salts. Officially documented manifestations include:

  • Gastrointestinal Distress: Severe diarrhea, abdominal cramps or pain, nausea, and vomiting.
  • Electrolyte Imbalance: A clinically significant loss of potassium and other essential body salts (electrolytes) due to excessive fluid output. This imbalance can lead to serious health issues.
  • Dehydration: Severe dehydration may result from excessive fluid loss and is a serious problem that can be indicated by symptoms such as feeling faint, dizziness, or headache.

Emergency Action Required

Official regulatory information emphasizes the need for immediate action in cases of suspected or known overdose:

If you or anyone else accidentally take too much of this medicine, or if you suspect you have taken an overdose, you must get immediate medical attention. Contact a healthcare professional or visit the nearest hospital right away. Timely intervention is crucial to manage dehydration and correct the potentially harmful salt imbalance.

Prolonged, excessive use (overuse) of the product, even if not a single large dose, is also cited as having overdose-related risks, specifically causing electrolyte disturbances, severe dehydration, and the potential for harm to intestinal function.

Therapeutic Uses of Cremalax

This medication is commonly used to help with symptoms related to physical discomfort associated with constipation, a condition involving episodic or fluctuating manifestations where bowel movements are infrequent and passing stools become difficult. The drug is generally considered a stimulant laxative that plays a role in managing symptoms that interfere with daily functioning.

The medication is also applied in clinical settings that involve acute or unstable symptom patterns to assist with bowel clearance relevant to preparation for diagnostic procedures such as colonoscopy. In therapeutic contexts, the main areas of use include the short-term symptomatic assistance of constipation and bowel cleansing applied in situations where patients experience preparation before a medical procedure. It contributes to easing the overall symptom load by facilitating easier bowel evacuation.

Quick Fact: Relief for symptoms related to physical discomfort

When used as part of supportive care, this agent helps support patients during difficult episodes by easing distress. This supports general well-being during symptomatic phases and contributes to improved comfort during periods of heightened symptoms, providing supportive relief when symptoms interfere with routine activities.

“This type of symptomatic management may assist with maintaining functional stability when episodes of discomfort are noticeable.”

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Cremalax, which contains the active ingredient sodium picosulfate, is a medicine with clear regulatory constraints on its use.

Eligibility Classification Population/Condition
Contraindicated (Must NOT use) Known hypersensitivity to the drug, gastrointestinal obstruction (ileus, intestinal perforation, or blockage), acute inflammatory bowel diseases, acute abdominal surgical conditions including appendicitis, and severe abdominal pain with nausea/vomiting.
Restricted Use (Use with Caution) Patients with severe dehydration or electrolyte imbalance, kidney disease, heart disease, or recent gastro-intestinal surgery.

Age-Related Rules: Use is not recommended for children under the age of 10 years as safety and efficacy data is typically not established for this group. Elderly patients should use it with caution due to an increased risk of dehydration and electrolyte disturbance.

Duration of Use: The medicine is intended only for short-term relief and is not recommended for prolonged use exceeding five days, as this may lead to dependence and electrolyte imbalances.

Pregnancy and Lactation: Use during pregnancy is not recommended unless considered clearly necessary and prescribed by a doctor. It is generally considered compatible with breast-feeding, though medical advice should still be sought.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the active component, Sodium Picosulfate, as established by government regulatory agencies.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with certain medicinal products may alter systemic exposure or increase specific risks. Antibiotics may reduce the efficacy of Sodium Picosulfate by interfering with its necessary conversion by colonic bacteria to the active metabolite. In contrast, Sodium Picosulfate may cause reduced systemic exposure of co-administered all oral medications, including those taken for other conditions, due to the increased speed of gastrointestinal transit.

Pharmacodynamic interactions exist with agents that affect fluid balance. The concurrent use of Diuretics or Corticosteroids may increase the risk of fluid and electrolyte disturbances. Similarly, co-administration with medications that lower the seizure threshold (e.g., Tricyclic Antidepressants) may increase the risk of seizure associated with electrolyte abnormalities.

Timing-Based Separation Requirements

To ensure proper absorption, specific oral medications such as Digoxin, Chlorpromazine, Penicillamine, Tetracycline, Fluoroquinolone antibiotics, and Oral Iron supplements require a mandatory separation interval. These products must be taken at least two hours before and not less than six hours after the administration of Sodium Picosulfate. Additionally, the consumption of Solid food and Dairy products is restricted during the treatment period for bowel cleansing, and Alcoholic beverages are prohibited.

Mechanism of Action

How Cremalax Works

Cremalax, containing sodium picosulfate, acts via mechanisms that stimulate colonic activity primarily within the large intestine. Its action is exerted through two primary mechanistic domains: regulating colonic smooth muscle motility and modulating fluid transport.


Local Activation and Metabolic Conversion

The compound is an inactive prodrug that must undergo metabolic conversion by bacterial sulfatase enzymes present in the lower gastrointestinal tract. This process generates the active metabolite, BHPM (bis-(p-hydroxy-phenyl)-pyridyl-2-methane), which restricts the compound's pharmacodynamic activity until its localized presence in the colon.


Dual Modulation of Colonic Function

BHPM engages two key pathways. First, it stimulates sensory nerve endings in the colon wall, initiating signaling sequences that increase the frequency and force of peristaltic contractions. This action results in a modified frequency and force of intestinal peristalsis. Second, the metabolite alters water and electrolyte transport by inducing a net secretion of fluid into the colonic lumen. This modification of luminal fluid dynamics limits water reabsorption and contributes to altered luminal volume and consistency, facilitating predictable physiological adjustments.

Dosage and Administration Information

Administration Scope

Instruction Details
Route of administration Oral administration in the form of tablets, liquid solution, or powder for reconstitution.
Dosing schedule For short-term use, the adult dose is generally 5 mg to 10 mg as a single oral dose. For bowel cleansing, a two-dose regimen (one packet or bottle per dose) is required, utilizing either a Split-Dose or Day-Before schedule.
Timing in relation to meals (if applicable) For short-term use, dosing is typically advised at bedtime. For cleansing, patients must adhere to a clear liquid diet from the start of the regimen, with no solid food or dairy allowed.
Preparation requirements (if applicable) Powder formulations must be reconstituted with cold water immediately before use; the solution must not be prepared in advance. Ready-to-drink solutions are administered directly.
Age-group administration rules The monotherapy for short-term use is typically indicated for patients age 10 years or older. The two-dose bowel cleansing regimen is approved for patients age 9 years or older.
Special procedural conditions Consumption of all liquids must cease at least two hours before the scheduled procedure time. Certain oral medications must be separated from the laxative administration by a minimum of 2 hours before and 6 hours after each dose.

Instruction Classifications (High-Level)

Classification Details
Administration method type Oral ingestion.
Frequency pattern Once daily (for intermittent use) or a two-dose cycle (for procedural use).
Basis of use Clinical and pharmacological protocols.
Use-context constraints Limited duration (maximum five days for short-term use); mandatory co-administration of specific volumes of clear liquids for procedural preparation.

Resulting Procedural Structure

Step sequence:

  • The first dose is taken (e.g., the evening before the procedure), followed by mandatory consumption of specific volumes of clear liquids within a defined period.
  • The second dose is taken at the prescribed interval (e.g., approximately 5 hours prior to the procedure).
  • All liquid intake must be stopped at least two hours before the scheduled medical procedure time.

Connection to the overall use protocol: The instructions establish distinct protocols based on use context, ranging from a simple, nightly oral dose for intermittent short-term relief to a time-sensitive two-dose cycle for procedural clearance. These protocols define the dose amount, timing, and mandatory fluid consumption, ensuring consistent application.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cremalax

Evidence for Use in Short-term Relief of Constipation

Research examined how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as functional constipation. Studies monitored outcomes related to physical discomfort. The research foundation includes randomized controlled trials (RCTs), many of which compared the preparation against an inactive substance (placebo).

In these studies, researchers focused on objective measurements, most commonly tracking the number of Complete Spontaneous Bowel Movements (CSBMs) over defined time intervals. They also applied studies examining patient-reported experiences, where participants noted how symptoms evolved in the observed populations, including outcomes related to perceived discomfort like bloating and changes in stool consistency. The research was observed in Adults with functional constipation.

Findings describe patterns observed in the studies related to the frequency of CSBMs over the four-week period, which was measured against placebo. Research highlights changes measured during the study period related to patient-reported outcomes describing perceived discomfort and quality of life. The high-quality evidence is primarily related to these short-term periods of assessment.

Evidence for Use in Bowel Cleansing Before Medical Procedures

Research also explored this preparation for use in a regimen to facilitate bowel cleansing before medical procedures, such as a colonoscopy. Studies were mainly active-controlled RCTs, meaning they compared the preparation against other existing cleansing agents.

Research primarily examined the Bowel Cleansing Success Rate, which was assessed by clinicians using standard, validated scales (like the BBPS or OBPS). Additional outcomes monitored included patient-reported factors such as the tolerability and acceptability of the preparation regimen.

Data show patterns related to the cleansing outcomes assessed in the observed populations when the preparation was assessed against other agents. Comparative evidence suggests that, in some trials, patient-reported outcomes describing perceived discomfort and tolerability were measured against high-volume preparations.

Long-term Outcomes and Durability of Effect

The evidence base from high-quality RCTs is relevant in trials assessing short-term or episodic symptom patterns, with follow-up durations that were limited, typically to four weeks.

The fact that longer-term effects are not fully established is a documented limitation of the prospective, randomized studies. Data show patterns related to use beyond the initial short-term period; however, this information is predominantly derived from observational or retrospective studies, which provide limited information for long-term outcomes.

Research in Special Populations

The preparation was studied for use in the Older Adult population in research exploring short-term symptom changes. It was also evaluated in Children and adolescents with functional constipation. Furthermore, the preparation was also evaluated in pediatric participants in bowel cleansing research.

For certain special populations not fully studied, such as pregnant or breastfeeding individuals, data for these specific groups remain insufficient in the formal research record, and certainty remains low regarding the effects in these populations.

Key Studies & References

  1. Sodium Picosulfate Long Term Safety - Consensus
  2. PEG-Asc Vs. SPMC for Bowel Preparation in Capsule-based Procedures | ClinicalTrials.gov
  3. A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy | ClinicalTrials.gov
  4. SUMMARY OF EVIDENCE - Treatments for Constipation: A Review of Systematic Reviews

Frequently Asked Questions (FAQ)

Common questions about Cremalax (FAQ)


Q: Does Cremalax require a prescription?

The official regulatory status of Cremalax, which contains sodium picosulfate, can vary depending on the country and the specific product formulation. Some preparations are available over-the-counter (OTC) for temporary, short-term use. However, combination products or high-strength formulations, such as those used for complete bowel cleansing, may be regulated as prescription-only.


Q: Does Cremalax always work within the same amount of time?

No. Official documents state that the active component usually begins to work between 6 and 10 hours after administration. This onset time may vary between individuals due to personal physiological factors. The specific formulation of the product, such as whether it includes other active ingredients, can also influence how quickly the medicine acts.


Q: Can Cremalax be used by people who are trying to manage their weight?

Official warnings from regulatory bodies state that stimulant laxatives, including sodium picosulfate, are not indicated for weight loss because they do not reduce the absorption of calories or nutrients. Regulatory warnings describe that misuse for weight management may lead to serious health risks, including dehydration and electrolyte imbalances.


Q: What happens if someone accidentally uses Cremalax for too long?

Regulatory guidance suggests limiting continuous daily use to five days or less. Prolonged excessive use may lead to fluid and electrolyte imbalances, particularly low potassium (hypokalaemia). Overuse is also associated with the risk of dependence on the medicine for normal bowel function.


Q: Is it normal for a person to feel bloated after using Cremalax?

Some patient information documents indicate that a person may experience bloating or abdominal discomfort. This can occur before the intended laxative effect starts, especially with the powder-for-solution formulations often used for medical procedure preparation. Other common reported side effects include abdominal cramping and pain.


Q: Is Cremalax considered generally safe for older adults?

The medicine has been evaluated for use in older adults. However, official documents note that the elderly are more susceptible to the risks of dehydration and electrolyte disturbance due to age-related changes. Official guidance indicates that its use should be managed with caution in this population.


Q: Are there different forms of Cremalax available (e.g., liquid, powder, tablet)?

Yes, regulatory documents list that the active ingredient, sodium picosulfate, is available in multiple dosage forms. These include standard tablets, oral solutions (liquids), and preparations as a powder for oral solution, which must be mixed with water before use.


Q: Do food or certain drinks affect how well Cremalax works?

For the short-term relief use, there are no specific food prohibitions mentioned in official documents. However, for the bowel cleansing preparation, regulatory instructions require consuming only clear fluids and strictly prohibit solid food and dairy products during the regimen to ensure effectiveness.


Q: Is Cremalax used for bowel preparation before medical procedures?

Yes, a combination formulation of the active ingredient is indicated (approved) for cleansing the colon. This preparation is used as part of a regimen before diagnostic procedures like a colonoscopy to ensure the bowel is clear for examination.


Q: Is Cremalax known to be habit-forming?

Official information discourages prolonged use of this type of laxative. The reason is that continuous use may lead to the development of dependence, meaning the body's natural bowel function may begin to rely on the medicine to work normally.


Q: Are there any specific lifestyle changes that are often suggested alongside Cremalax?

Regulatory guidance suggests that this medicine should only be used if a therapeutic effect cannot be achieved by changes in diet or the administration of bulk-forming agents. Official documentation suggests that diet and administration of bulk-forming agents should be explored before using this medicine.


Q: How often do people report feeling nauseous when using Cremalax?

Nausea is listed in regulatory adverse reaction summaries, but it is typically classified as an Uncommon side effect. This classification means that the event is reported in less than 1 in 100 patients who use the medicine.


Q: Does Cremalax contain gluten or common allergens?

Official regulatory documents list all inactive ingredients, known as excipients, for each specific product formulation. The full list of ingredients is available for individuals to review for the presence of gluten or known allergens.


Q: Why do some Cremalax products have a flavor added?

Regulatory records sometimes mention that inactive ingredients are added for flavoring or to help with palatability. This is done because patient acceptability and tolerability are factors measured in studies, particularly for large-volume solutions used for bowel preparation.


Q: Are there any restrictions on driving or operating machinery while using Cremalax?

Official warnings advise caution when driving or operating machinery. This is because potential side effects, such as dizziness or syncope (fainting), may occur. These effects are sometimes related to severe abdominal spasms or the body's response to the rapid fluid loss.


Q: What are the primary differences between Cremalax formulations?

The different formulations of the medicine vary by their route of administration, such as a tablet versus a liquid solution. They also differ by their intended use—monotherapy is for short-term relief, while combination products are for pre-procedural bowel cleansing, which affects the final concentration and ingredient composition.


Q: Does Cremalax help with hard stool, or only with frequency?

Official regulatory descriptions of the mechanism of action state that the medicine works to increase the frequency of peristaltic contractions and by changing fluid dynamics in the colon. This alteration assists in the softening of feces by limiting the reabsorption of water, helping with both consistency and frequency.


Q: What kind of studies were used to determine the effectiveness of Cremalax?

The evidence base used by regulatory authorities to approve the medicine includes high-quality research. This research consists of randomized controlled trials (RCTs), where outcomes like the frequency of bowel movements for constipation and cleansing success rates for bowel preparation were objectively measured.


Q: Does the time of day a person uses Cremalax matter?

Yes, for the short-term relief of occasional constipation, official administration is typically advised at bedtime. This timing is chosen because the expected onset of effect is 6–10 hours later, which aligns with a morning bowel movement. For bowel cleansing, strict, time-sensitive dosing schedules are established.


Q: What is the typical age range for people who use Cremalax?

Official age-related rules note that the medicine is generally indicated for adults. It is not recommended for children under 10 years for short-term use. Specific combination products for procedural cleansing have been approved for patients 9 years of age and older.


Q: Is the mechanism of action of Cremalax described the same way across all regulatory bodies?

Yes, regulatory bodies consistently describe the medicine as an inactive prodrug that is activated by bacteria in the colon. The active form then works as a stimulant to increase the movement of the large intestine and helps modulate fluid transport.


Q: Are there specific foods that should be avoided when taking Cremalax?

For bowel cleansing, regulatory instructions explicitly state that solid food, dairy products, and anything colored red or purple must be avoided. For the use of the medicine for short-term constipation relief, no specific food prohibitions are listed in the official patient documents.


Q: Do official patient leaflets mention interactions with herbal remedies?

While specific herbal remedies are not always listed individually, official documents advise caution with concurrent use of all oral products. The medicine may reduce the systemic exposure of any co-administered oral products, including herbal remedies, due to the increased speed of transit through the gut.


Q: What is the purpose of the non-active ingredients in Cremalax?

The non-active ingredients, or excipients, serve necessary functional purposes. These functions include maintaining the medicine's stability, ensuring its proper form (e.g., dissolution of a powder), and improving the product’s palatability through flavoring.


Q: Is Cremalax intended for long-term or short-term use?

Regulatory guidance clearly indicates the product is intended only for the short-term relief of occasional constipation. Official warnings state that prolonged use of this medicine, typically exceeding five days, is generally not recommended due to the risks of dependence and electrolyte loss.


Q: Can someone use Cremalax if they are recovering from bowel surgery?

Official safety warnings advise caution in patients who have a history of recent gastro-intestinal surgery due to potential risks. Furthermore, the medicine is contraindicated (must not be used) if a suspected intestinal obstruction or perforation is present.


Q: Has there been research on using Cremalax in children?

Yes, regulatory records confirm that the preparation was evaluated in children and adolescents in studies concerning functional constipation. It was also assessed in pediatric participants as part of research for its use in bowel cleansing procedures.


Q: Are there any common over-the-counter pain relievers that interact with Cremalax?

The medicine may cause reduced systemic exposure of all oral medications taken at the same time, including oral pain relievers, due to increased speed of gastrointestinal transit. Some specific oral medications must be separated by time from the administration of Cremalax.


Q: Can Cremalax be taken at the same time as antacids?

Official instructions advise against taking oral medications within a specified period—often 1 hour—before and after starting the product for bowel cleansing. Since some antacids are oral medications, a timing separation is typically necessary to ensure the proper absorption of the antacid.


Q: Does taking Cremalax affect the absorption of vitamins or minerals?

Regulatory information indicates that due to the increased gastrointestinal transit speed, the medicine may cause reduced systemic exposure of all oral medications. This effect can potentially include the absorption of orally administered vitamins or minerals, requiring careful timing of administration.


Q: Are there any known issues with drinking alcohol while using Cremalax?

Alcoholic beverages are officially prohibited during the treatment period for bowel cleansing. Additionally, official documents advise caution because the risk of side effects like dizziness or syncope may be increased when drinking alcohol while using this medication.


Q: How does Cremalax affect the body's electrolyte balance?

Excessive or prolonged use can lead to fluid and electrolyte imbalance, most notably causing low potassium levels (hypokalaemia). Official warnings note that the preparation may also interact with other medicines, such as diuretics, which could increase the risk of this disturbance.


Q: Is it necessary to drink extra water when using Cremalax?

Regulatory guidance, especially for the bowel cleansing protocol, stresses that adequate hydration is required. Additional clear fluids are necessary to compensate for the fluid loss that the product causes and to address the risk of dehydration.

How should Cremalax be stored and disposed of?

How to Store and Dispose of Cremalax

Official regulatory guidelines dictate specific storage and disposal requirements for Cremalax (Sodium Picosulfate).


Storage Requirements

Store the medicine at room temperature (20 C to 25 C) and keep the product from freezing or refrigerating. It is mandatory to store the medicine in its original package with the container tightly closed to protect from moisture.

For child safety, the medicine must be kept out of the sight and reach of children.

Stability and Disposal

Once certain powder forms are opened or reconstituted, the product must be used immediately, and any unused portion must be discarded; do not use the medicine after the expiry date. To dispose of unused or expired Cremalax, do not throw it away via wastewater or household waste. Consult a pharmacist for the proper method for discarding the medicine to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cremalax found in:

A-Z Index: